- Protein Name
- Protein kinase C iota type
- Gene Name
- PRKCI
- Organism
-
Homo sapiens
- Function
- Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
6 |
6 |
6.0 |
| PIF |
3 |
2 |
2.5 |
| DRS |
18 |
11 |
11.0 |
| MT3 |
23 |
2 |
13.0 |
| AAS |
11 |
5 |
10.0 |
| LBP |
9 |
9 |
9.0 |
| PDIG |
25 |
9 |
15.0 |
| ATP |
22 |
1 |
8.0 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
DFG site |
PIF site |
DRS site |
DEF site |
EDI site |
MT3 site |
AAS site |
LBP site |
CMP site |
PDIG site |
ATP site |
PMP site |
| Total Druggable Structures per Site |
0 |
0 |
0 |
1 |
0 |
0 |
3 |
0 |
0 |
0 |
2 |
3 |
0 |
|
3A8X
|
0 |
0 |
2 |
11 |
0 |
0 |
18 |
11 |
9 |
0 |
16 |
18 |
0 |
|
3ZH8
|
0 |
0 |
0 |
18 |
0 |
0 |
23 |
0 |
0 |
0 |
9 |
22 |
0 |
|
3A8W
|
0 |
0 |
0 |
0 |
0 |
0 |
20 |
10 |
0 |
0 |
15 |
17 |
0 |
|
1ZRZ
|
6 |
0 |
3 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
25 |
15 |
0 |